ArticleAsian Pacific journal of cancer prevention : APJCP2025
Dual Repurposing Strategy: Rivaroxaban and Ciprofloxacin as a Synergistic Anticancer Therapy in Cervical Cancer: Insight into Inhibition of Metastasis via Targeting the EMT Pathway.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study assessed the anticancer and antimetastatic impact of rivaroxaban-ciprofloxacin mixture and explored its molecular mechanism by examining its ability to target the epithelial-mesenchymal transition (EMT) pathway.
methodsFollowing incubation periods of 24 and 72 hours, HeLa and normal human fibroblast (NHF) cell lines were employed to investigate the anticancer and safety properties of rivaroxaban, ciprofloxacin, rivaroxaban-ciprofloxacin mixture, and carboplatin, with concentrations varying from 0.1 to 1000 µg/ml. The wound healing assay (WHA) of cervical cancer cells was employed to assess the anti-metastatic effects of the mixture at three time points: 0, 12, and 24 hours.. A combination index (CI) and selectivity toxicity index (SI) score were estimated to assess the potential synergistic effects of the mixture's components and their selectivity toxicity. A computational molecular docking simulation was conducted to evaluate the binding affinity of rivaroxaban and ciprofloxacin to different regulatory signals in the EMT pathway.
resultsThe MTT and WHS assays outcomes revealed that the rivaroxaban-ciprofloxacin mixture possesses anticancer and antimetastatic properties. This combination significantly suppresses the growth of cervical cancer cells more effectively than carboplatin, rivaroxaban, or ciprofloxacin alone. Additionally, the mixture results in a 98% delay of cancer cell migration after 24 hours of incubation. Furthermore, the mixture's cytotoxicity on NHF cells was significantly lower than carboplatin. The combination of rivaroxaban and ciprofloxacin showed synergistic cytotoxic effects, as confirmed by the CI score. Also, it displays a selective cytotoxicity toward cancer cells, as indicated by the SI score. The molecular docking study results revealed that the most favorable interactions for rivaroxaban and ciprofloxacin occurred with the matrix metalloprotease and Tankyrase enzyme, with docking scores of -9 kcal/mol and -8.9 kcal/mol, respectively.
conclusionThe study's findings and the established pharmacokinetic and safety profiles of mixture drugs suggest that the pairing of rivaroxaban and ciprofloxacin offers a promising and safer option for treating cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.